Sofosbuvir impurity N - 10mM in DMSO , CAS No.1394157-34-6

CAS: 1394157-34-6 Cat. No.: S655894 Summenformel: C₂₀H₂₅FN₃O₉P Molekulargewicht: 501.40 PubChem CID: 67440929

QUALITÄT & REINHEIT 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

Sofosbuvir impurity N, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

IC50& Target:HCV

Spezifikationen

Spezifikationen & Reinheit

10mM in DMSO

Biochemische und physiologische Mechanismen

Sofosbuvir impurity N, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

Storage

Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Namen und Kennungen

Isomere SMILES

C[C@@H](C(=O)OC)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3

PubChem CID

67440929

Molekulargewicht

501.40

Application Protocols

No assay kits or bioassay protocols are provided for this item. The following are general protocols for using impurity standards in analytical chemistry; adapt to your laboratory SOPs.

General LC standard preparation:

• Allow vial to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation.
• Weigh an appropriate amount quickly and accurately (analytical balance). Record lot purity/potency from the CoA.
• Dissolve in dry DMSO or MeCN to form a primary stock (e.g., 0.5–5 mg/mL). Vortex/sonicate briefly if needed.
• Prepare serial dilutions in MeCN/H2O (with 0.1% formic acid or 5 mM ammonium acetate as applicable) to generate a calibration curve spanning anticipated levels.
• Filter if particulate is observed (0.2 µm PTFE or nylon, compatibility permitting).

System suitability and identification:

• Inject blank, placebo, parent API, impurity N standard, and spiked samples to confirm peak identity and resolution.
• Use LC–MS to verify m/z and fragmentation patterns per CoA/MS data.

Documentation:

• Record preparation dates, storage conditions, injection sequences, and instrument parameters. Archive raw data and calculations consistent with data integrity requirements.

Biological Roles

This product is supplied as a pharmaceutical impurity standard and is not intended for biological or clinical use.

General context (not item-specific claims):

• Sofosbuvir is a nucleotide prodrug; its impurities can arise from process-related byproducts or degradants of the phosphoramidate/uridine scaffold. Such impurities are analytically monitored to ensure drug substance/product quality per ICH Q3A/B.
• Impurity standards like “impurity N” enable trace-level detection and quantification in biological matrices during nonclinical method development only as analytical markers, not as active agents.

Important notes:

• No biological function, target engagement, or pharmacology is assigned or implied for this impurity standard.
• Do not use in cell culture or in vivo studies intended for therapeutic evaluation. For research use only.

If metabolism studies are conducted (purely analytical):

• Co-chromatography with authentic impurity standards can help differentiate metabolite peaks from process impurities during LC–MS analyses of samples, improving assignment confidence without inferring biological activity.

Buffer Applications

Not typically applicable. This product is an organic impurity standard rather than a buffering agent.

Practical analytical note (general):

• When used in LC or LC–MS workflows, volatile aqueous buffers such as 5–10 mM ammonium acetate or formate (pH ~3–6) are commonly paired with acetonitrile or methanol. Select the buffer system based on the impurity’s ionization behavior established from the CoA/MS data.
• Avoid nonvolatile salts if MS detection is required.

Green Alternatives

When developing analytical methods or handling solutions of sofosbuvir-related impurities, solvent choice can impact environmental footprint. While this product’s structure-specific constraints are unknown, greener method design is often feasible.

Greener considerations (general):

• Prefer acetonitrile or ethanol over halogenated solvents (e.g., dichloromethane) for sample prep where chemically compatible.
• For reversed-phase LC, use water/ethanol or water/acetonitrile gradients; methanol is acceptable but may increase backpressure.
• Employ volatile, low-toxicity buffers (ammonium acetate/formate) at minimal effective concentrations instead of phosphate buffers for LC–MS.
• Minimize DMSO use to the smallest necessary stock volumes; for working solutions, dilute into greener solvent systems promptly.

Comparison (general tendencies):

• Acetonitrile: low viscosity, low UV cut-off, good MS compatibility; derived from petrochemical sources but efficient in use due to lower pressures and shorter run times.
• Ethanol: bio-based availability, safer profile; higher viscosity and UV cut-off can limit use at high aqueous content and short columns.
• Methanol: readily available, but toxicity and higher backpressure vs MeCN.

Operational strategies:

• Shorten runtimes with efficient columns (e.g., sub-2 µm or superficially porous) to reduce solvent consumption.
• Implement multiplexed gradients and reuse mobile phase bottles to cut waste.
• Collect organic waste streams separately for recycling programs where available.

Pharmaceutical Uses

No excipient or therapeutic use is claimed. For research use only.

Role in pharmaceutical quality (general, non-item-specific):

• Reference standard for ICH Q3A(R2)/Q3B(R2) impurity control in sofosbuvir drug substance/product.
• Supports development and validation of stability-indicating methods (ICH Q2(R2)): specificity, linearity, accuracy, precision, LOQ/LLOD, robustness.
• Facilitates impurity qualification studies by enabling accurate spiking in stress samples and formulation matrices.
• Can be used for setting system suitability criteria (retention time windows, resolution vs. adjacent peaks) and for establishing relative response factors (RRFs) in quantitative assays, when justified by data.

Documentation and compliance:

• Use lot-specific purity/potency values from the CoA for preparing calibration standards and for uncertainty budgeting.
• Maintain traceability records: lot number, storage conditions, preparation logs, chromatographic raw data.
• If alignment with pharmacopeial monographs is required, verify that the supplied material corresponds to the designated “impurity N” structure and meets monograph acceptance criteria (where available).

Physical Properties

Item-specific physico-chemical data are not provided in the product listing.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not applicable/Not typically reported for complex organic impurity standards; refer to CoA/Spec Sheet if available.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• LogP, pKa, refractive index: Not specified for this item; refer to CoA/Spec Sheet.

General literature guidance (context; not item specifications):

• Sofosbuvir-related impurities are commonly handled as solids or concentrated solutions and are typically soluble in polar aprotic solvents such as DMSO and acetonitrile, and variably in methanol or aqueous-organic mixtures depending on ionizable groups present.
• If phosphate/phosphoramidate functionality is present (typical in sofosbuvir analogs), ionization can influence aqueous solubility and chromatographic retention; buffers in the pH 2.5–6 range are frequently used for LC.

Practical note:

• Determine solubility empirically on a small scale using a solvent screen (DMSO, MeCN, MeOH, IPA, H2O/MeCN with 0.1% formic acid or ammonium acetate). Always rely on the lot-specific CoA for any quantitative properties.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Context for impurity standards (general, not item-specific claims):

• Identity confirmation typically includes 1H/13C NMR, LC–MS/HRMS, and purity by HPLC/UPLC (UV and/or ELSD/MS). Where applicable, 31P NMR may be used for phosphoramidate-containing structures. Water content may be assessed by Karl Fischer. Residual solvents are often profiled by GC.
• Analytical suitability: Impurity reference standards are commonly supplied at ≥95% purity by HPLC with a well-resolved chromatographic profile to support ICH Q2(R2) method validation (specificity, linearity, accuracy, precision, LOQ). This statement is general and does not constitute a specification for this item.
• Trace stabilizers: None stated for this item. If present in a specific lot, stabilizers will be disclosed on the CoA. Stabilizers can influence UV background and LC–MS ionization.
• Documentation: Lot-specific CoA will list assay, identification data, and recommended chromatographic conditions if applicable.

How to use the grade information in practice:

• For quantitative impurity assays, use the exact lot potency (if provided) to normalize standard solutions.
• Retain aliquots for long-term method verification and cross-lot comparability.
• If compendial harmonization (e.g., Ph. Eur./USP) is required, verify that the supplied material matches the monograph-defined impurity N structure and acceptance criteria.

Reaction and Applications

This product is intended primarily as an analytical reference standard for impurity profiling and method development associated with sofosbuvir. It is not typically used as a reagent or catalyst.

Analytical and development applications (general):

• System suitability and peak identification in HPLC/UPLC assays for sofosbuvir drug substance and drug product, enabling specificity in stability-indicating methods.
• Calibration/linearity standards for quantifying impurity N across ICH reporting, identification, and qualification thresholds.
• Forced degradation studies: tracking formation/consumption under acid/base hydrolysis, oxidative stress (e.g., H2O2), thermal/humidity stress, and photolysis.
• LC–MS/MS method development: optimizing ionization (ESI±), collision energies, and MRM transitions based on the lot-specific MS data.
• Orthogonal methods: confirmation by NMR and HRMS to support structure elucidation and co-elution checks.

Practical tips:

• Prepare a primary stock in dry DMSO or MeCN at a known gravimetric concentration; store aliquots at −80°C as indicated for this item.
• Use amber vials to mitigate photolysis if the impurity contains chromophores susceptible to light degradation (general consideration for nucleoside/prodrug impurities).
• Verify solution stability by re-injecting a control standard after extended autosampler residence (e.g., 24–48 h at 4–8°C) to establish method robustness.

Reaction Conditions

Not applicable as a reagent. The following guidance pertains to analytical method conditions (general literature practices for sofosbuvir-related impurity assays) and should be optimized empirically.

Reversed-phase LC (typical starting conditions):

• Column: C18, 100–150 mm × 2.1–4.6 mm, 1.7–5 µm.
• Mobile phase A: Water with 0.05–0.1% formic acid or 5–10 mM ammonium formate/acetate.
• Mobile phase B: Acetonitrile (or methanol).
• Gradient: 5–40% B over 10–20 min as a scouting method; adjust based on retention.
• Flow: 0.2–1.0 mL/min (scale with column ID), 30–40°C.
• Detection: UV 210–220 nm and/or 254–270 nm; LC–MS (ESI±) for confirmation.

Stress testing (for method development):

• Acid/base hydrolysis, oxidative (e.g., low % H2O2), thermal/photolytic exposures to generate degradants for specificity challenges. Quench prior to analysis to preserve impurity profiles.

Solution stability checks:

• Assess bench-top, autosampler (4–8°C), and freeze–thaw stability using replicate injections; establish acceptance criteria for area% drift and retention time shifts.

Note: These are general conditions from analytical practice and are not item-specific specifications.

Safety and Handling

Safety information specific to this item has not been provided in the listing. Always consult the SDS for authoritative guidance.

• GHS classification, signal word, pictograms, H-statements: Not specified for this item; refer to SDS/CoA.
• General precautions (good laboratory practice):
  • Handle in a chemical fume hood; avoid inhalation of dusts/aerosols.
  • Wear appropriate PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile). Consider double-gloving for extended handling.
  • Prevent contact with skin and eyes; wash thoroughly after handling.
  • Avoid ingestion/injection. For research use only.
• Storage incompatibilities: Separate from strong oxidizers and strong acids/bases unless compatibility is known. Protect from moisture if the material is hygroscopic or hydrolytically labile (common for phosphate/phosphoramidate-containing species in general literature).
• Special risks (general for organic impurity standards):
  • Potential for unknown acute toxicity; minimize exposure and scale.
  • If the compound contains acid-/base-labile groups (common in nucleotide prodrug chemistry), avoid prolonged exposure to extreme pH or elevated temperature.
• First-aid overview (general):
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention if irritation persists.
  • Inhalation: Move to fresh air; seek medical attention if symptoms occur.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
• Waste: Collect as organic hazardous waste; do not discharge to drains. Follow institutional and local regulations.

Solvent Selection

Because the precise structure is not disclosed here, begin with a conservative solvent screen and confirm by small-scale tests.

Practical approach for preparing analytical standards (general guidance):

• Primary stock solvent: DMSO (anhydrous) is a robust first choice due to broad solvating power and LC compatibility at low injection volumes.
• Alternative organic solvents: Acetonitrile (MeCN) and methanol (MeOH) commonly dissolve sofosbuvir-related impurities; isopropanol (IPA) may help if solubility is limited.
• Aqueous compatibility: If the analyte ionizes, it may be soluble in H2O/organic mixtures (e.g., 50:50 MeCN/H2O) with 0.05–0.1% formic acid or 5–10 mM ammonium acetate for LC–MS.

Miscibility/compatibility (general literature values):

• DMSO, MeCN, MeOH are mutually miscible with water and widely used in reversed-phase LC.
• For MS detection, volatile modifiers (formic acid, ammonium formate/acetate) are preferred over nonvolatile buffers.

Selection tips:

• Choose DMSO for high-concentration long-term stocks and dilute into MeCN/H2O just before injection to reduce on-column precipitation.
• For UV-based HPLC, MeCN often affords lower backpressure and lower UV cut-off versus MeOH; choose MeOH when enhanced solvating power for polar impurities is needed.
• Filter final working solutions (0.2 µm PTFE/nylon) if compatible to remove particulates; avoid PVDF with strong organic if unsure.

Storage and Reconstitution

• Storage conditions (item-specific): Store at -80°C.
• Shipping (item-specific): Shipped on dry ice packs + cold packs to maintain low temperature during transit.

General handling and reconstitution:

• Upon receipt, inspect the package condition. Transfer immediately to a −80°C freezer. Minimize time at ambient temperature.
• Before opening, allow the sealed container to equilibrate to room temperature in a desiccator to avoid moisture condensation on cold material.
• If supplied as a solid: Prepare a primary stock in dry, high-purity DMSO or acetonitrile at a known concentration. Mix gently to dissolve; brief sonication may help. If supplied as a solution, verify concentration on the CoA before use.
• Aliquoting: Dispense single-use aliquots into inert, amber vials to avoid repeated freeze–thaw cycles.
• Freeze–thaw guidance: Avoid multiple cycles. Thaw on ice or at room temperature, use promptly, and refreeze remaining aliquots only once if necessary.
• Light/moisture protection: Use amber containers; purge headspace with inert gas if the material is moisture- or oxygen-sensitive (consult CoA/SDS).
• Stability: Not specified for this item; refer to CoA/Spec Sheet for shelf-life and solution stability.

Research use note: For research use only. Not for human or veterinary use.

Structure and Identity

Brief overview: This item is a designated process/degradation impurity associated with the antiviral prodrug sofosbuvir, supplied for analytical and research use.

• Product name: Sofosbuvir impurity N
• CAS: 1394157-34-6
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Synonyms/Type: Designated “impurity N” of sofosbuvir (ICH/compendial-style impurity designation).

Structural notes (general information):

• As an impurity of sofosbuvir, it is structurally related to the parent phosphoramidate/uridine prodrug scaffold; however, the exact substitution pattern that defines “impurity N” is not provided here. Do not assume structure without the supplied CoA or reference monograph.
• Functional group expectations (general, literature): sofosbuvir-related impurities often retain nucleoside/nucleotide-like motifs (e.g., uracil/uridine core, phosphate/phosphoramidate features) or arise from transformations of the alkyl/aryl ester or amino acid masking groups. This is provided as context only and not as a specification for this specific item.

2D description (generic): Without the disclosed structure, a text rendering cannot be provided. Consult the analytical documentation (1H/13C/31P NMR, LC–MS, HRMS) accompanying the lot for definitive structural identification.

Synthetic Utility

This item is not typically used as a synthetic building block; its primary role is as an analytical reference standard.

General considerations (context only):

• If the structure of impurity N were disclosed and compatible, such species can occasionally inform retrosynthetic analysis of the parent drug by revealing plausible side reactions or protective-group liabilities in phosphoramidate prodrug chemistry.
• Process chemists may synthesize impurity N intentionally in small scale to confirm impurity pathways and establish controls, but the purchased standard is intended for identification/quantification rather than as a reagent.

Guidance for users:

• Avoid using this material to drive chemical transformations or as a coupling partner unless its structure and reactivity are fully characterized from the CoA and primary literature.
• Preserve the majority of the material for analytical calibration to ensure continuity of quality-control testing across campaigns.

Target Specificity

Not applicable. This product is not a biological targeting reagent (e.g., antibody, ligand, inhibitor). No target specificity is assigned. Use solely as an analytical reference standard associated with sofosbuvir impurity profiling.

Häufig gestellte Fragen

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 1394157-34-6, the molecular formula is C20H25FN3O9P, and the molecular weight is 501.40 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.